Errata to Combined FDA and Applicant ODAC Briefing Document

Oncologic Drugs Advisory Committee (ODAC) Meeting

February 9, 2021

BLA 125514 Supplement-089

Drug name: Pembrolizumab

Applicant: Merck Sharp & Dohme Corp.

This document contains errata to the combined FDA and Applicant ODAC Briefing Document. The erroneous text is followed by the correction in bold below.

1. Page 13, Section 2.1.2 Immune Checkpoint Inhibition for Treatment of TNBC

- IMpassion130, evaluated atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in patients with untreated metastatic triple-negative breast cancer. This trial showed only a modest improvement in its primary PFS endpoint in the tumor PD-L1 CPS≥1 population. OS was not statistically significant in the PD-L1 unselected population and due to the pre-specified hierarchical testing plan OS in the PD-L1 CPS ≥1 could not be formally tested. This resulted in an accelerated approval for patents with tumor PD-L1 CPS≥1 and clinical benefit needs to be confirmed.
- IMpassion131, not referenced by the Applicant, evaluated atezolizumab plus paclitaxel compared to placebo plus paclitaxel in patients with unresectable locally advanced or metastatic triple-negative breast cancer and no prior chemotherapy or targeted therapy for advanced disease. This trial failed to meet its primary PFS endpoint in the tumor PD-L1 CPS ≥1 and PD-L1-unselected populations. Concerningly, interim OS results favored the control arm [38].

Corrected to read as:

- IMpassion130, evaluated atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in patients with untreated metastatic triple-negative breast cancer. This trial showed only a modest improvement in its primary PFS endpoint in the tumor PD-L1-**expressing** population. OS was not statistically significant in the PD-L1 unselected population and due to the pre-specified hierarchical testing plan OS in the **PD-L1-expressing population** could not be formally tested. This resulted in an accelerated approval for patents with **tumors that express** PD-L1 **(PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥1% of tumor area) as determined by an FDA-approved test** and clinical benefit needs to be confirmed.
- IMpassion131, not referenced by the Applicant, evaluated atezolizumab plus paclitaxel compared to placebo plus paclitaxel in patients with unresectable locally advanced or metastatic triple-negative breast cancer and no prior chemotherapy or targeted therapy for advanced disease. This trial failed to meet its primary PFS endpoint in the tumor PD-L1**-expressing** and PD-L1-unselected populations. Concerningly, interim OS results favored the control arm [38].